OBJECTIVES: The aim of this study was to evaluate the correlation between QT interval (QT) and serum sotalol concentration following a single low dose of oral and intravenous sotalol. METHODS:Fifteen healthy volunteers received 75 mg intravenous sotalol over 2.5 h and 80 mg oral sotalol in a random order. Serum sotalol concentrations and 12-lead electrocardiograms were obtained simultaneously at baseline and 7 times following dosings. Rate-corrected QT (QTc) was calculated by the Bazett, Fridericia and Framingham formulas. Linear regression analysis was performed between sotalol concentrations and QT measurements. RESULTS:Significant QT prolongation was seen at very low sotalol doses and serum concentrations. QTc intervals calculated by the Framingham and Fridericia formulas showed the strongest and virtually identical correlations with serum sotalol concentration (r >or= 0.97, p < 0.001) following oral and intravenous administrations. The equation QTc = 0.0342 (sotalol concentration) + 398 closely predicted actual QTc at any sotalol concentration. CONCLUSIONS: A strong correlation was observed between serum sotalol concentration and QTc prolongation across the entire concentration range. Low-dose sotalol caused significant QT prolongation. At similar concentrations, intravenous and oral sotalol caused similar QT and QTc effects. Knowing the QT effect can be used to guide further dose increase. Copyright 2010 S. Karger AG, Basel.
RCT Entities:
OBJECTIVES: The aim of this study was to evaluate the correlation between QT interval (QT) and serum sotalol concentration following a single low dose of oral and intravenous sotalol. METHODS: Fifteen healthy volunteers received 75 mg intravenous sotalol over 2.5 h and 80 mg oral sotalol in a random order. Serum sotalol concentrations and 12-lead electrocardiograms were obtained simultaneously at baseline and 7 times following dosings. Rate-corrected QT (QTc) was calculated by the Bazett, Fridericia and Framingham formulas. Linear regression analysis was performed between sotalol concentrations and QT measurements. RESULTS: Significant QT prolongation was seen at very low sotalol doses and serum concentrations. QTc intervals calculated by the Framingham and Fridericia formulas showed the strongest and virtually identical correlations with serum sotalol concentration (r >or= 0.97, p < 0.001) following oral and intravenous administrations. The equation QTc = 0.0342 (sotalol concentration) + 398 closely predicted actual QTc at any sotalol concentration. CONCLUSIONS: A strong correlation was observed between serum sotalol concentration and QTc prolongation across the entire concentration range. Low-dose sotalol caused significant QT prolongation. At similar concentrations, intravenous and oral sotalol caused similar QT and QTc effects. Knowing the QT effect can be used to guide further dose increase. Copyright 2010 S. Karger AG, Basel.
Authors: Sharan L Campleman; Jeffery Brent; Anthony F Pizon; Joshua Shulman; Paul Wax; Alex F Manini Journal: Clin Toxicol (Phila) Date: 2020-04-07 Impact factor: 4.467
Authors: V Gotta; F Cools; K van Ammel; D J Gallacher; S A G Visser; F Sannajust; P Morissette; M Danhof; P H van der Graaf Journal: Br J Pharmacol Date: 2015-07-21 Impact factor: 8.739
Authors: Santiago O Valdés; Christina Y Miyake; Mary C Niu; Caridad M de la Uz; S Yukiko Asaki; Andrew P Landstrom; Andrew E Schneider; Craig G Rusin; Raajen Patel; Wilson W Lam; Jeffrey J Kim Journal: Heart Rhythm Date: 2018-07-10 Impact factor: 6.343
Authors: Verena Gotta; Zhiyi Yu; Frank Cools; Karel van Ammel; David J Gallacher; Sandra A G Visser; Frederick Sannajust; Pierre Morissette; Meindert Danhof; Piet H van der Graaf Journal: Pharmacol Res Perspect Date: 2016-11-17
Authors: Josée Bouchard; Greene Shepherd; Robert S Hoffman; Sophie Gosselin; Darren M Roberts; Yi Li; Thomas D Nolin; Valéry Lavergne; Marc Ghannoum Journal: Crit Care Date: 2021-06-10 Impact factor: 9.097
Authors: Andreas D Meid; Irene Bighelli; Sarah Mächler; Gerd Mikus; Giuseppe Carrà; Mariasole Castellazzi; Claudio Lucii; Giovanni Martinotti; Michela Nosè; Giovanni Ostuzzi; Corrado Barbui; Walter E Haefeli Journal: Ther Adv Psychopharmacol Date: 2017-08-28